NCT03975647 2026-03-30A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeagen Inc.Phase 3 Active not recruiting466 enrolled 17 charts
NCT04957212 2024-07-26Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast CancerCinnagenPhase 3 Completed214 enrolled 16 charts